Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 163

1.

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Lung Cancer. 2012 Jun;76(3):478-85. doi: 10.1016/j.lungcan.2011.12.015. Epub 2012 Jan 25.

PMID:
22277104
[PubMed - indexed for MEDLINE]
Free Article
2.

Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.

Nordstrom BL, Luo W, Fraeman K, Whyte JL, Nordyke RJ.

J Manag Care Pharm. 2008 Nov-Dec;14(9):858-69.

PMID:
19006442
[PubMed - indexed for MEDLINE]
Free Article
3.

Update on erythropoiesis-stimulating agents and clinical trials in oncology.

Aapro M, Spivak JL.

Oncologist. 2009;14 Suppl 1:6-15. doi: 10.1634/theoncologist.2009-S1-6. Review.

PMID:
19762512
[PubMed - indexed for MEDLINE]
Free Article
4.

Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke MJ, Weingart O, Kluge S, Piper M, Napoli M, Rades D, Steensma D, Djulbegovic B, Fey MF, Ray-Coquard I, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007303. doi: 10.1002/14651858.CD007303.pub2. Review.

PMID:
19588423
[PubMed - indexed for MEDLINE]
5.

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Cancer Sci. 2013 Apr;104(4):481-5. doi: 10.1111/cas.12105. Epub 2013 Mar 15.

PMID:
23331490
[PubMed - indexed for MEDLINE]
6.

Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis.

Hedenus M, Osterborg A, Tomita D, Bohac C, Coiffier B.

Leuk Lymphoma. 2012 Nov;53(11):2151-8. doi: 10.3109/10428194.2012.684347. Epub 2012 May 22.

PMID:
22497574
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA.

J Clin Oncol. 2009 Jun 10;27(17):2838-47. doi: 10.1200/JCO.2008.19.1130. Epub 2009 Apr 20.

PMID:
19380447
[PubMed - indexed for MEDLINE]
8.

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Vansteenkiste J, Pirker R, Massuti B, Barata F, Font A, Fiegl M, Siena S, Gateley J, Tomita D, Colowick AB, Musil J; Aranesp 980297 Study Group.

J Natl Cancer Inst. 2002 Aug 21;94(16):1211-20.

PMID:
12189224
[PubMed - indexed for MEDLINE]
Free Article
9.

Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?

Bormanis J, Quirt I, Chang J, Kouroukis CT, MacDonald D, Melosky B, Verma S, Couture F.

Crit Rev Oncol Hematol. 2013 Aug;87(2):132-9. doi: 10.1016/j.critrevonc.2012.12.010. Epub 2013 Jan 26. Review.

PMID:
23357249
[PubMed - indexed for MEDLINE]
10.

Chemotherapy-induced anemia: the story of darbepoetin alfa.

Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M.

Curr Med Res Opin. 2013 Apr;29(4):325-37. doi: 10.1185/03007995.2013.766593. Epub 2013 Feb 11. Review.

PMID:
23323876
[PubMed - indexed for MEDLINE]
11.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H.

Br J Cancer. 2010 Jan 19;102(2):301-15. doi: 10.1038/sj.bjc.6605498. Epub 2010 Jan 5.

PMID:
20051958
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Update on safety of ESAs in cancer-induced anemia.

Glaspy J.

J Natl Compr Canc Netw. 2012 May;10(5):659-66. Review.

PMID:
22570294
[PubMed - indexed for MEDLINE]
13.

Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.

Canon JL, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Legg J, Pujol B, Bridges K.

Med Oncol. 2012 Sep;29(3):2291-9. doi: 10.1007/s12032-011-0103-x. Epub 2011 Nov 13.

PMID:
22081263
[PubMed - indexed for MEDLINE]
14.

Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.

Pirker R, Ramlau RA, Schuette W, Zatloukal P, Ferreira I, Lillie T, Vansteenkiste JF.

J Clin Oncol. 2008 May 10;26(14):2342-9. doi: 10.1200/JCO.2007.15.0748.

PMID:
18467726
[PubMed - indexed for MEDLINE]
15.

Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits.

Hill JW, Shreay S, McGarvey N, De AP, Hess GP, Corey-Lisle PK.

Support Care Cancer. 2013 Nov;21(11):2957-65. doi: 10.1007/s00520-013-1830-7. Epub 2013 Jun 12.

PMID:
23756616
[PubMed - indexed for MEDLINE]
16.

The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.

Polsky D, Eremina D, Hess G, Hill J, Hulnick S, Roumm A, Whyte JL, Kallich J.

Pharmacoeconomics. 2009;27(9):755-65. doi: 10.2165/11313860-000000000-00000.

PMID:
19757869
[PubMed - indexed for MEDLINE]
17.

Anemia management in oncology and hematology.

Spivak JL, Gascón P, Ludwig H.

Oncologist. 2009;14 Suppl 1:43-56. doi: 10.1634/theoncologist.2009-S1-43. Review.

PMID:
19762516
[PubMed - indexed for MEDLINE]
Free Article
18.

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.

Ross SD, Allen IE, Henry DH, Seaman C, Sercus B, Goodnough LT.

Clin Ther. 2006 Jun;28(6):801-31. Review. Erratum in: Clin Ther. 2007 May;29(5):985-6.

PMID:
16860166
[PubMed - indexed for MEDLINE]
19.

Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.

Bohlius J, Tonia T, Schwarzer G.

Acta Haematol. 2011;125(1-2):55-67. doi: 10.1159/000318897. Epub 2010 Dec 8. Review.

PMID:
21150188
[PubMed - indexed for MEDLINE]
Free Article
20.

Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.

Reitan JF, van Breda A, Corey-Lisle PK, Shreay S, Cong Z, Legg J.

Clin Drug Investig. 2013 May;33(5):383-9. doi: 10.1007/s40261-013-0078-9.

PMID:
23553358
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk